Brevirtide combination therapy demonstrates efficacy in rendering compensated chronic hepatitis delta virus RNA undetectable

Data from Gilead’s Phase IIb study MYR204 published in the New England Journal of Medicine found that the brevirtide/peginterferon alfa-2a combination was more effective at rendering HDV RNA undetectable compared with brevirtide 10 mg monotherapy in treating chronic hepatitis D.